Skip to main content

Advertisement

SpringerLink
Log in

Prognostic factors in patients with glioblastoma multiforme: focus on the pathologic variants

  • Original article
  • Published:
Acta Neurologica Belgica Aims and scope Submit manuscript

A Correction to this article was published on 16 July 2019

This article has been updated

Abstract

The aim of this study was to offer predicting factors for survival in adult patients with glioblastoma multiforme. 153 consecutive patients with high-grade glioma (WHO grade IV) were studied in Imam Reza hospital, Kermanshah University of Medical Science, Kermanshah, Iran, between April 2003 and April 2017. All patients treated with surgical resection and standard postoperative radiotherapy (54 Gy). Using the patients’ charts and electronic medical records system, the following data were obtained: gender, age, Karnofsky performance status (KPS) score on admission, primary vs. secondary type, extent of surgery, tumor location, tumor size, necrosis size, use of Temozolomide (TMZ), pathology subtype, and immunohistochemistry results. Patients were followed from the time of the surgery until the death occurred. Overall survival (OS) and progression-free survival (PFS) were calculated by the Kaplan–Meier method. Survival time curves for various subgroups were compared by the log-rank test. The impact of the suggested prognostic factors on survival was evaluated by univariate and multivariate analyses. Age, gender, KPS, extent of surgery, tumor location, necrosis size, and reoperation in recurrence had not any statistically significant effect on survival. Univariate analysis revealed a significant impact on outcome for pathology subtype (PFS: P < 0.001, OS: P < 0.001), tumor type (primary vs. secondary) (PFS: P = P < 0.001, OS: P < 0.001), tumor size (PFS: P = 0.044, OS: P = 0.04), TMZ therapy (PFS: P < 0.001, OS: P < 0.001), P53 (PFS: P < 0.001, OS: P < 0.001), and Ki67 (PFS: P < 0.001, OS: P < 0.001). In multivariate analysis, independent favorable prognostic factors for survival were pathology subtype (PFS: P < 0.001, OS: P < 0.001), type (PFS: P < 0.001, OS: 0.012), TMZ (PFS: P < 0.001, OS: P < 0.001), P53 (PFS: P < 0.001, OS: P < 0.001), and Ki67 (PFS: P < 0.001, OS: P < 0.001). The results suggest that pathology subtype, primary vs. secondary type, TMZ therapy, P53, and Ki 63 may play an important role in the survival of patients with glioblastoma multiforme. There is no relationship detected between age, gender, KPS, tumor size and location, necrosis size, extent of surgery, reoperation in recurrence, and patient survival.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

Data availability

All data are available from the corresponding author upon reasonable request.

Change history

  • 16 July 2019

    Unfortunately, the third author name was incorrectly published in the original publication. The complete correct name should read as follows.

References

  1. D’Alessio A, Proietti G, Sica G, Scicchitano BM (2019) Pathological and molecular features of glioblastoma and its peritumoral tissue. Cancers 11(4):2–19

    Article  Google Scholar 

  2. Eriksson M, Kahari J, Vestman A, Hallmans M, Johansson M, Bergenheim AT et al (2019) Improved treatment of glioblastoma—changes in survival over two decades at a single regional Centre. Acta oncologica (Stockholm, Sweden). 58(3):334–341

    Article  Google Scholar 

  3. Guden M, Ayata HB, Ceylan C, Kilic A, Engin K (2016) Prognostic factors effective on survival of patients with glioblastoma: Anadolu Medical Center experience. Indian J Cancer 53(3):382–386

    CAS  Google Scholar 

  4. Harat M, Blok M, Harat A, Soszynska K (2019) The impact of adjuvant radiotherapy on molecular prognostic markers in gliomas. OncoTargets Ther 12:2215–2224

    Article  CAS  Google Scholar 

  5. Chaudhry NS, Shah AH, Ferraro N, Snelling BM, Bregy A, Madhavan K et al (2013) Predictors of long-term survival in patients with glioblastoma multiforme: advancements from the last quarter century. Cancer Invest 31(5):287–308

    Article  Google Scholar 

  6. Myung JK, Cho HJ, Kim H, Park CK, Lee SH, Choi SH et al (2014) Prognosis of glioblastoma with oligodendroglioma component is associated with the IDH1 mutation and MGMT methylation status. Transl Oncol 7(6):712–719

    Article  Google Scholar 

  7. Roh TH, Kang SG, Moon JH, Sung KS, Park HH, Kim SH et al (2019) Survival benefit of lobectomy over gross-total resection without lobectomy in cases of glioblastoma in the noneloquent area: a retrospective study. J Neurosurg. https://doi.org/10.3171/2018.12.JNS182558

    Article  Google Scholar 

  8. Rigamonti A, Imbesi F, Silvani A, Lamperti E, Agostoni E, Porcu L et al (2019) Prognostic nutritional index as a prognostic marker in glioblastoma: data from a cohort of 282 Italian patients. J Neurol Sci 400:175–179

    Article  Google Scholar 

  9. Smoll NR, Schaller K, Gautschi OP (2013) Long-term survival of patients with glioblastoma multiforme (GBM). J Clin Neurosci 20(5):670–675

    Article  Google Scholar 

  10. Piccolo SR, Frey LJ (2013) Clinical and molecular models of glioblastoma multiforme survival. Int J Data Min Bioinform 7(3):245–265

    Article  Google Scholar 

  11. Karsy M, Gelbman M, Shah P, Balumbu O, Moy F, Arslan E (2012) Established and emerging variants of glioblastoma multiforme: review of morphological and molecular features. Folia Neuropathol 50(4):301–321

    Article  Google Scholar 

  12. Woodworth GF, Garzon-Muvdi T, Ye X, Blakeley JO, Weingart JD, Burger PC (2013) Histopathological correlates with survival in reoperated glioblastomas. J Neurooncol 113(3):485–493

    Article  Google Scholar 

  13. Zhang LY, Ge HJ, Wang LM, Zhao LH, Liu L, Zhang DJ et al (2019) Prognostic implication of alterations in epidermal growth factor receptor and MGMT in glioblastoma. Zhonghua bing li xue za zhi Chinese J Pathol 48(3):186–191

    CAS  Google Scholar 

  14. Sales AHA, Bette S, Barz M, Huber T, Wiestler B, Ryang YM et al (2019) Role of postoperative tumor volume in patients with MGMT-unmethylated glioblastoma. J Neuro-oncol 142(3):529–536

    Article  CAS  Google Scholar 

  15. Alexiou GA, Vartholomatos E, Tsamis KI, Peponi E, Markopoulos G, Papathanasopoulu VA et al (2019) Combination treatment for glioblastoma with temozolomide, DFMO and radiation. J BUON 24(1):397–404

    Google Scholar 

  16. Henker C, Kriesen T, Schneider B, Glass A, Scherer M, Langner S et al (2019) Correlation of Ki-67 index with volumetric segmentation and its value as a prognostic marker in glioblastoma. World Neurosurg 125:e1093–e1103

    Article  Google Scholar 

  17. Syed M, Liermann J, Verma V, Bernhardt D, Bougatf N, Paul A et al (2018) Survival and recurrence patterns of multifocal glioblastoma after radiation therapy. Cancer Manag Res 10:4229–4235

    Article  Google Scholar 

  18. Wang X, Liu YH, Xie F, You C, Mao Q (2013) A clinical and molecular study of long-term survival glioblastomas. Zhonghua wai ke za zhi [Chin J Surg] 51(2):166–170

    Google Scholar 

  19. Li WB, Tang K, Chen Q, Li S, Qiu XG, Li SW et al (2012) MRI manifestions correlate with survival of glioblastoma multiforme patients. Cancer Biol Med 9(2):120–123

    Google Scholar 

  20. Delgado-Lopez PD, Corrales-Garcia EM (2016) Survival in glioblastoma: a review on the impact of treatment modalities. Clin Transl Oncol 18(11):1062–1071

    Article  CAS  Google Scholar 

  21. De Barros A, Attal J, Roques M, Nicolau J, Sol JC, Cohen-Jonathan-Moyal E et al (2019) Impact on survival of early tumor growth between surgery and radiotherapy in patients with de novo glioblastoma. J Neuro-oncol 142(3):489–497

    Article  Google Scholar 

  22. Chaichana KL, Martinez-Gutierrez JC, De la Garza-Ramos R, Weingart JD, Olivi A, Gallia GL et al (2013) Factors associated with survival for patients with glioblastoma with poor pre-operative functional status. J Clin Neurosci 20(6):818–823

    Article  Google Scholar 

  23. Byun J, Kim YH, Nam SJ, Park JE, Cho YH, Kim HS et al (2019) Comparison of survival outcomes between partial resection and biopsy for primary glioblastoma: a propensity score-matched study. World Neurosurg 121:e858–e866

    Article  Google Scholar 

  24. Back M, Jayamanne D, Cove N, Wheeler H, Khasraw M, Guo L et al (2018) Optimising outcomes for glioblastoma through subspecialisation in a regional cancer centre. Brain Sci 8(10):186

    Article  CAS  Google Scholar 

  25. Ahmadipour Y, Jabbarli R, Gembruch O, Pierscianek D, Darkwah Oppong M, Dammann P et al (2019) Impact of multifocality and molecular markers on survival of glioblastoma. World Neurosurg 122:e461–e466

    Article  Google Scholar 

  26. Palmer JD, Bhamidipati D, Shukla G, Sharma D, Glass J, Kim L et al (2019) Rapid early tumor progression is prognostic in glioblastoma patients. Am J Clin Oncol 42(5):481–486

    Article  Google Scholar 

Download references

Acknowledgements

We appreciate the clinical Research Development Center of Imam Reza Hospital for their wise advice.

Funding

There was no external source of funding.

Author information

Authors and Affiliations

  1. Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran

    Ehsan Alimohammadi, Seyed Reza Bagheri, Alireza Sadeghsalehi, Parisa Rizevandi, Zahra Rezaie & Alireza Abdi

Authors
  1. Ehsan Alimohammadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Seyed Reza Bagheri
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alireza Sadeghsalehi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Parisa Rizevandi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zahra Rezaie
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Alireza Abdi
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

EA and SRB had the idea for this study. EA and PR participated in outlining the concept and design. ZR and ASS did the data acquisition. EA and AA did the statistical analysis and wrote the first draft of the manuscript. EA, SRB, ASS, and AA revised the final manuscript. All authors have read and approved the manuscript.

Corresponding author

Correspondence to Ehsan Alimohammadi.

Ethics declarations

Conflict of interest

All authors declare that they have no conflict of interest.

Consent for publication

Not applicable.

Ethics approval and consent to participate

The study received ethics approval by the Kermanshah University of Medical Science Ethics Committee.

Informed consent

All participants provided informed consent prior to their participation.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original version of this article was revised to update the 3rd author name.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alimohammadi, E., Bagheri, S.R., Sadeghsalehi, A. et al. Prognostic factors in patients with glioblastoma multiforme: focus on the pathologic variants. Acta Neurol Belg 120, 1341–1350 (2020). https://doi.org/10.1007/s13760-019-01171-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13760-019-01171-x

Keywords

Search

Navigation